(Q36817100)

16 August 2017

1 reference

title

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer (English)

1 reference

16 August 2017

Alain M Monnier

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

627-634

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Aromatase inhibitors and bone health in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.627

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.627

1 reference

16 August 2017

1 reference